By Colin Kellaher

Eli Lilly & Co. on Tuesday said mirikizumab met its main endpoints in a 12-week Phase 3 induction study evaluating its efficacy and safety in patients with moderate to severe ulcerative colitis.

The Indianapolis drugmaker said mirikizumab met the primary endpoint of clinical remission at week 12 compared with placebo and achieved all key secondary endpoints, including reduced bowel urgency, clinical response, endoscopic remission, symptomatic remission and improvement in endoscopic histologic inflammation.

Eli Lilly said a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in patients who have completed the 12-week induction study is ongoing.

The company said it plans to continue the maintenance study through 52 weeks, with full results from both studies expected in early 2022.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

03-16-21 0728ET